Form 4: Rhythm Pharma Director's Trust Receives Stock Distribution

A director at Rhythm Pharmaceuticals, Edward T. Mathers, reported a change in beneficial ownership through a pro rata stock distribution to his revocable trust.

Summary

• Edward T. Mathers, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), reported a change in his beneficial ownership of the company's common stock.
• On March 2, 2026, NEA Partners 13, L.P. made a pro rata distribution of Common Stock to its limited partners for no consideration.
• The Edward Timothy Mathers Revocable Trust, for which Mr. Mathers is the trustee, received 4,198 shares of Rhythm Pharmaceuticals Common Stock in this distribution.
• Following this transaction, Mr. Mathers indirectly beneficially owns 9,969 shares through the Mathers Trust and directly owns 7,000 shares, totaling 16,969 shares.
• Mr. Mathers disclaims beneficial ownership of any portion of the securities held by the Mathers Trust in which he has no pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine reporting of a change in beneficial ownership for an insider, not indicative of operational performance or strategic shifts.

Future Outlook

This filing is a routine report of a change in beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a standard disclosure of an insider's change in beneficial ownership, specifically a non-sale/purchase distribution. It does not provide insights into broader industry trends or competitive positioning, as it focuses solely on an individual's stock holdings.

Related Party Transactions

• NEA Partners 13, L.P. made a pro rata distribution of Common Stock to its limited partners, including The Edward Timothy Mathers Revocable Trust, for no consideration. This represents a transfer of shares between entities associated with the reporting person.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a change in how an existing director holds shares, not a market transaction or a change in the company's fundamentals.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Transaction, Beneficial Ownership, Stock Distribution, Director, Edward T. Mathers